None listed
Conditions
Brief summary
The antioxidants acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and a-lipoic acid (ALA) are shown to be involved in protecting cells from oxidative damage. Recently, a study performed in the mouse model and in smaller human studies showed a clear benefit of using the combination of the three antioxidants on embryo development as well as implantation potential and foetal growth. We therefore want to study the possible advantage of using a medium containing these three known antioxidants compared with the standard medium currently being used in our IVF laboratories. Mainly we want to investigate whether the combination of these three antioxidants may favour embryo development in human IVF.
Interventions
- Participation in this research involves patients agreeing to scientists culturing their embryos in either standard culture media or culture media supplemented with antioxidants.
- The study will compare embryo morphokinetics, blastocyst development and implantation using two different media, G-TL versus G-TL supplemented with antioxidants (10uM Acetyl-L-carnitine (ALC), 10uM N-acetyl-L-cysteine (NAC) and 5uM a-lipoic acid (ALA))
- the supplementation of the antioxidants occurs during media p
- Participation in this research involves patients agreeing to scientists culturing their embryos in either standard culture media or culture media supplemented with antioxidants. - The study will compare embryo morphokinetics, blastocyst development and implantation using two different media, G-TL versus G-TL supplemented with antioxidants (10uM Acetyl-L-carnitine (ALC), 10uM N-acetyl-L-cysteine (NAC) and 5uM a-lipoic acid (ALA)) - the supplementation of the antioxidants occurs during media preparation, i.e. prior to gamete collection and fertilization of eggs. Fertilised eggs are then cultured in this media. From day 1 of embryo culture, embryos will be placed in the media to which they have been randomised too. - The embryologist (scientist) is responsible for administering the intervention
Sponsors
Melbourne IVF
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
• Couples with female, male or unexplained infertility intending to undergo IVF or ICSI and where there are no medical contraindications to perform the treatment. • The couple should have received verbal and written information/consent about the study. • Blastocyst culture and fresh transfer on day 5 of a single embryo. • Concomitant medications (eg; use of any oral antioxidants) will be recorded
Exclusion criteria
• Previous participation in the study. • Use of PGS where frozen embryo transfer is planned • Testicular biopsy patients (TESA/TESE) • Total freeze and no transfer possible.
Outcome results
None listed